enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
3.770
-0.050 (-1.31%)
Feb 21, 2025, 4:00 PM EST - Market closed
enVVeno Medical Employees
enVVeno Medical had 31 employees as of December 31, 2023. The number of employees increased by 1 or 3.33% compared to the previous year.
Employees
31
Change (1Y)
1
Growth (1Y)
3.33%
Revenue / Employee
n/a
Profits / Employee
-$685,129
Market Cap
66.11M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
NVNO News
- 3 days ago - enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Accesswire
- 3 days ago - One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum - Accesswire
- 15 days ago - Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting - Accesswire
- 2 months ago - enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe - Accesswire
- 3 months ago - enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website - Accesswire
- 3 months ago - enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium - Accesswire
- 3 months ago - enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval - Accesswire
- 3 years ago - Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann - Accesswire